Humanization and characterization of the anti-HLA-DR antibody 1D10

Sheri A KOSTELNY; Brian K LINK; J. Yun TSO; Max VASQUEZ; Brett H JORGENSEN; Hong WANG; William C HALL; George J WEINER

doi:10.1002/ijc.1366

Back

Humanization and characterization of the anti-HLA-DR antibody 1D10

Journal article

Open access

Peer reviewed

Humanization and characterization of the anti-HLA-DR antibody 1D10

Sheri A KOSTELNY, Brian K LINK, J. Yun TSO, Max VASQUEZ, Brett H JORGENSEN, Hong WANG, William C HALL and George J WEINER

International journal of cancer, Vol.93(4), pp.556-565

2001

DOI: 10.1002/ijc.1366

PMID: 11477560

Files and links (1)

url

https://doi.org/10.1002/ijc.1366View

Published (Version of record) Open Access

Abstract

1D10 is a previously described antibody that binds to cells from a majority of B-cell malignancies. The current studies were designed to further evaluate the antigen specificity of 1D10 and its potential as an immunotherapeutic agent. Studies with transfectants and immunoprecipitation demonstrated that 1D10 recognizes some, but not all, of the human HLA-DR beta chains. Both normal and malignant B cells can express the 1D10 antigen. A humanized version of 1D10 was produced using CDR grafting. The resulting antibody has an affinity that is similar to that of the parental murine antibody. In addition, the humanized antibody is capable of inducing complement-mediated cytotoxicity, antibody-dependent cell cytotoxicity, and direct apoptosis of 1D10-expressing B cells. Based on these in vitro anti-tumor activities, we conclude humanized 1D10 deserves further evaluation as an immunotherapeutic agent.

Antineoplastic Agents

Immunotherapy

Biological and medical sciences

Medical sciences

Pharmacology. Drug treatments

Details

Title: Subtitle: Humanization and characterization of the anti-HLA-DR antibody 1D10
Creators: Sheri A KOSTELNY - Protein Design Labs, Inc., Fremont, CA, United States
Brian K LINK - Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, IA, United States
J. Yun TSO - Protein Design Labs, Inc., Fremont, CA, United States
Max VASQUEZ - Protein Design Labs, Inc., Fremont, CA, United States
Brett H JORGENSEN - Protein Design Labs, Inc., Fremont, CA, United States
Hong WANG - Protein Design Labs, Inc., Fremont, CA, United States
William C HALL - Pathology Associates International, Frederick, MD, United States
George J WEINER - Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, IA, United States
Resource Type: Journal article
Publication Details: International journal of cancer, Vol.93(4), pp.556-565
DOI: 10.1002/ijc.1366
PMID: 11477560
NLM abbreviation: Int J Cancer
ISSN: 0020-7136
eISSN: 1097-0215
Publisher: Wiley-Liss
Language: English
Date published: 2001
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
Record Identifier: 9984094730002771

Metrics

19 Record Views

49 Times Cited - Web of Science